Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort

References

1. 1.↵
   1. Nita DA,
   2. Mole SE,
   3. Minassian BA

   . Neuronal ceroid lipofuscinoses. Epileptic Disord 2016;18:73–88 doi:10.1684/epd.2016.0844 pmid:27629553

   CrossRefPubMed
2. 2.↵
   1. Kaminiów K,
   2. Kozak S,
   3. Paprocka J

   . Recent insight into the genetic basis, clinical features, and diagnostic methods for neuronal ceroid lipofuscinosis. Int J Mol Sci 2022;23:5729 doi:10.3390/ijms23105729

   CrossRefPubMed
3. 3.↵
   1. Sleat DE,
   2. Donnelly RJ,
   3. Lackland H, et al

   . Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 1997;277:1802–05 doi:10.1126/science.277.5333.1802 pmid:9295267

   Abstract/FREE Full Text
4. 4.↵
   1. Mukherjee AB,
   2. Appu AP,
   3. Sadhukhan T, et al

   . Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses. Mol Neurodegener 2019;14:4 doi:10.1186/s13024-018-0300-6 pmid:30651094

   CrossRefPubMed
5. 5.↵
   1. Schulz A,
   2. Ajayi T,
   3. Specchio N, et al

   ; CLN2 Study Group. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018;378:1898–907 doi:10.1056/NEJMoa1712649 pmid:29688815

   CrossRefPubMed
6. 6.↵
   1. Löbel U,
   2. Sedlacik J,
   3. Nickel M

   , et al. Volumetric description of brain atrophy in neuronal ceroid lipofuscinosis, 2: supratentorial gray matter shows uniform disease progression. AJNR Am J Neuroradiol 2016;37:1938–43 doi:10.3174/ajnr.A4816 pmid:27231226

   Abstract/FREE Full Text
7. 7.↵
   1. D'Incerti L

   . MRI in neuronal ceroid lipofuscinosis. Neurol Sci 2000;21:S71–73 doi:10.1007/s100720070043 pmid:11073231

   CrossRefPubMed
8. 8.↵
   1. Aydın K,
   2. Havali C,
   3. Kartal A, et al

   . MRI in CLN2 disease patients: subtle features that support an early diagnosis. Eur J Paediatr Neurol 2020;28:228–36 doi:10.1016/j.ejpn.2020.07.009 pmid:32855042

   CrossRefPubMed
9. 9.↵
   1. Vanhanen SL,
   2. Raininko R,
   3. Santavuori P, et al

   . MRI evaluation of the brain in infantile neuronal ceroid-lipofuscinosis., Part 1: postmortem MRI with histopathologic correlation. J Child Neurol 1995;10:438–43 doi:10.1177/088307389501000603 pmid:8576552

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Biswas A,
    2. Krishnan P,
    3. Amirabadi A, et al

    . Expanding the neuroimaging phenotype of neuronal ceroid lipofuscinoses. AJNR Am J Neuroradiol 2020;41:1930–36 doi:10.3174/ajnr.A6726 pmid:32855186

    Abstract/FREE Full Text
11. 11.↵
    1. Vanhanen SL,
    2. Raininko R,
    3. Autti T, et al

    . MRI evaluation of the brain in infantile neuronal ceroid-lipofuscinosis. Part 2: MRI findings in 21 patients. J Child Neurol 1995;10:444–50 doi:10.1177/088307389501000604 pmid:8576553

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Autti T,
    2. Joensuu R,
    3. Aberg L

    . Decreased T2 signal in the thalami may be a sign of lysosomal storage disease. Neuroradiology 2007;49:571–78 doi:10.1007/s00234-007-0220-6 pmid:17334752

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Chang M,
    2. Cooper JD,
    3. Sleat DE, et al

    . Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2008;16:649–56 doi:10.1038/mt.2008.9 pmid:18362923

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Vuillemenot BR,
    2. Kennedy D,
    3. Cooper JD, et al

    . Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Mol Genet Metab 2015;114:281–93 doi:10.1016/j.ymgme.2014.09.004 pmid:25257657

    CrossRefPubMed
15. 15.↵
    1. Schulz A,
    2. Specchio N,
    3. de Los Reyes E, et al

    . Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Lancet Neurol 2024;23:60–70 doi:10.1016/S1474-4422(23)00384-8 pmid:38101904

    CrossRefPubMed
16. 16.↵
    Batten Disease Family Association. http://www.bdfa-uk.org.uk/research-and-resources/brineura-for-cln2/-. Accessed February 25, 2024
17. 17.↵
    1. Dyke JP,
    2. Sondhi D,
    3. Voss HU, et al

    . Brain region-specific degeneration with disease progression in late infantile neuronal ceroid lipofuscinosis (CLN2 disease). AJNR Am J Neuroradiol 2016;37:1160–69 doi:10.3174/ajnr.A4669 pmid:26822727

    Abstract/FREE Full Text
18. 18.↵
    1. Hochstein JN,
    2. Schulz A,
    3. Nickel M, et al

    . Natural history of MRI brain volumes in patients with neuronal ceroid lipofuscinosis 3: a sensitive imaging biomarker. Neuroradiology 2022;64:2059–67 doi:10.1007/s00234-022-02988-9 pmid:35699772

    CrossRefPubMed
19. 19.↵
    1. Knoernschild K,
    2. Johnson HJ,
    3. Schroeder KE, et al

    . Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model. Sci Rep 2023;13:5146 doi:10.1038/s41598-023-32071-z pmid:36991106

    CrossRefPubMed
20. 20.↵
    1. Fischl B

    . FreeSurfer. Neuroimage 2012;62:774–81 doi:10.1016/j.neuroimage.2012.01.021 pmid:22248573

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Bates D,
    2. Mächler M,
    3. Bolker B, et al

    . Fitting linear mixed-effects models using lme4. J Stat Soft 2015;67:1–48 doi:10.18637/jss.v067.i01

    CrossRefPubMed
22. 22.↵
    1. Kim S

    . ppcor: an r package for a fast calculation to semi-partial correlation coefficients. Commun Stat Appl Methods 2015;22:665–74 doi:10.5351/CSAM.2015.22.6.665 pmid:26688802

    CrossRefPubMed
23. 23.↵
    1. Nickel M,
    2. Simonati A,
    3. Jacoby D

    , et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2018;2:582–90 doi:10.1016/S2352-4642(18)30179-2 pmid:30119717

    CrossRefPubMed
24. 24.↵
    1. Baker EH,
    2. Levin SW,
    3. Zhang Z

    , et al. MRI brain volume measurements in infantile neuronal ceroid lipofuscinosis. AJNR Am J Neuroradiol 2017;38:376–82 doi:10.3174/ajnr.A4978 pmid:27765741

    Abstract/FREE Full Text
25. 25.↵
    1. Chow N,
    2. Hwang KS,
    3. Hurtz S, et al

    ; Alzheimer’s Disease Neuroimaging Initiative. Comparing 3T and 1.5T MRI for mapping hippocampal atrophy in the Alzheimer’s Disease Neuroimaging Initiative. AJNR Am J Neuroradiol 2015;36:653–60 doi:10.3174/ajnr.A4228 pmid:25614473

    Abstract/FREE Full Text